EP Patent

EP3789394A1 — Crystalline forms c of obeticholic acid

Assigned to Intercept Pharmaceuticals Inc · Expires 2021-03-10 · 5y expired

What this patent protects

The present invention relates to crystalline form C of obeticholic acid, pharmaceutical compositions thereof and medicinal indications thereof in the treatment of FXR mediated diseases.

USPTO Abstract

The present invention relates to crystalline form C of obeticholic acid, pharmaceutical compositions thereof and medicinal indications thereof in the treatment of FXR mediated diseases.

Drugs covered by this patent

Ocaliva (OBETICHOLIC ACID) · Intercept Pharms Inc

Patent Metadata

Patent number: EP3789394A1
Jurisdiction: EP
Classification: —
Expires: 2021-03-10
Drug substance claim: No
Drug product claim: No
Assignee: Intercept Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.